INTELLIGENT PEPTIDE DISCOVERY

Unique Artificial Intelligence for groundbreaking drug discovery

WHO WE ARE

Pepticom was founded in 2011 by a select team of multidisciplinary PhD scientists and MBAs from the Hebrew University of Jerusalem with the vision of, for the first time, streamlining peptide drug discovery by introducing Artificial Intelligence. Our technology enables the discovery of the most advanced peptide-based drug candidates more quickly, more comprehensively and more successfully. Pepticom operates in various markets; past successful discoveries include peptide molecules related to Metabolic disease and Alzheimer’s disease and as Immuno-modulators. Learn more about the challenge and our solution, here.